# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from...
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(1.63) per share. This is a 5.23 percent increase over losses of...